CSL Cuts FY26 Guidance After Interim CEO’s 90-Day Review

CSL ( (AU:CSL) ) has provided an update.

CSL’s interim chief executive Gordon Naylor has completed a 90-day review of the biopharmaceutical group, concluding that major growth and transformation initiatives are progressing but that financial benefits will take longer to emerge than previously expected. He highlighted improving commercial execution, early momentum in recent product launches, and cost-efficiency measures across the business, reinforcing confidence that CSL can return to profitable growth and position the company and its next CEO for success.

Following the review, CSL cut its fiscal 2026 guidance, now forecasting revenue of about $15.2 billion and NPATA of around $3.1 billion on a constant-currency basis, excluding restructuring costs and impairments. The downgrade reflects a planned normalisation of U.S. immunoglobulin channel inventory, pricing-driven market value declines for albumin in China despite stable volumes and share gains, and additional headwinds from the Middle East conflict, slower HEMGENIX growth and iron competition.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$205.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

More about CSL

CSL Limited is a Melbourne-based biopharmaceutical company with core strengths in plasma collections and influenza vaccines. The group operates globally in the plasma-derived therapies and vaccine markets, serving growing demand for immunoglobulins, albumin and seasonal flu shots while pursuing transformation and efficiency programs to support long-term profitable growth.

YTD Price Performance: -29.67%

Average Trading Volume: 1,503,391

Technical Sentiment Signal: Sell

Current Market Cap: A$57.41B

See more data about CSL stock on TipRanks’ Stock Analysis page.